AKT1 and lung carcinoma: Prucalopride, a dihydrobenzofuran formamide compound and highly selective 5-HT4 receptor agonist, was reported by Chen et al. to inhibit the proliferation, invasion, and migration of lung cancer cells by blocking the PI3K/Akt/mTOR signaling pathway (Chen M. et al., 2019).